anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present disclosure describes two click reactions to sequentially polymerize and then functionalize hydrogel microparticles to provide therapeutic agent-functionalized crosslinked hydrogel microparticles. The two click reactions have one common reactive group, and are non-interfering with respect to one another. The therapeutic agents can be released from the hydrogel microparticles over time as the hydrogel degrades, or the therapeutic agents can be released from the hydrogel microparticles by enzymatic degradation or hydrolysis. In some embodiments, the biological function of the therapeutic agents can be preserved or enhanced when covalently bound to the hydrogel microparticles. The present disclosure also provides methods for the production of hydrogel cell culture substrates. The methods overcome the hurdle of protein functionalization through the implementation of an advanced but simple chemical strategy that involves modifying a protein of interest with chemical groups (e.g., tetrazines) that are able to react with complementary chemical groups (e.g., norbornenes) immobilized within a mechanically-tunable hydrogel.
A loss of 5% or more of body weight occurred in 7% of venlafaxine hydrochloride extended-release capsules-treated and 2% of placebo-treated patients in the short-term placebo-controlled major depressive disorder trials. The discontinuation rate for weight loss associated with venlafaxine hydrochloride extended-release capsules was 0.1% in major depressive disorder studies. In placebo-controlled Social Anxiety Disorder trials, 4% of the venlafaxine hydrochloride extended-release capsules-treated and 1% of the placebo-treated patients sustained a loss of 7% or more of body weight during up to 6 months of treatment. None of the patients receiving venlafaxine hydrochloride extended-release capsules in Social Anxiety Disorder studies discontinued for weight loss.

The safety and efficacy of venlafaxine therapy in combination with weight loss agents, including phentermine, have not been established. Coadministration of venlafaxine hydrochloride extended-release capsules and weight loss agents is not recommended. Venlafaxine hydrochloride extended-release capsules are not indicated for weight loss alone or in combination with other products.
Pressure ulcers are a significant healthcare problem for the growing number of nursing home residents in the United States and around the world. Pressure ulcers diminish quality of life, exact a devastating loss of function, increase the risk of death in geriatric populations and raise healthcare costs. Costs for the management of pressure ulcers in the US likely exceeds $6.4 billion annually, with a prevalence of approximately 12% in the high risk LTC population. A previous clinical trial at the University of Pittsburgh studied the effects of seat cushions on pressure ulcer incidence and found that when a skin protection seat cushion is used with a properly fitted wheelchair there is a significant reduction in incidence. The data led the investigators to question whether having a properly fitted wheelchair also has a significant effect on pressure ulcer incidence. This clinical trial investigate this question by randomizing subjects into a control group that receives a skin protection cushion and wheelchair training for use in their facility supplied wheelchair, or a treatment group that receives a skin protection cushion, wheelchair training and a new custom-fitted wheelchair. We expect that the treatment group will have a lower incidence of pressure ulcers.
PURPOSE: A cosmetic composition including brine manufactured by using ion-exchange resin is provided to enhance elastase suppressing activity and collagen synthesis effects. CONSTITUTION: A cosmetic composition includes brine manufactured by using ion-exchange resin as active ingredient. The brin has the conductivity of 92 mS/cm-96 mS/cm. An ion exchange process electrodialysis method uses mono valent cation selected ion-exchange resin and mono valent anion selection ion-exchange resin. The ion exchange process electrodialysis method is performed at 20 deg. Celsius, and under a condition of the speed of 750 mL/min, a current of the voltage of 15V, and a limit current value of 3A for 5 -7 hours. The cosmetic composition is for wrinkle improvement or whitening. A manufacturing method of brine having the wrinkle improving activation and whitening activity comprises the following steps: injecting the brine into the ion exchange process electrodialytic device; and performing the ion exchange electrodialysis method at 20 deg. Celsius, and under a condition of the speed of 750 mL/min, a current of the voltage of 15V, and a limit current value of 3A for 5 -7 hours.
Patients admitted to an adult intensive care unit for more than 24 hours who develop new onset atrial fibrillation during their ICU admission will be included. After discharge from ICU patients will undergo continuous ECG monitoring via VitalConnect patch for 14 days or until hospital discharge, whichever is shortest. They will undergo a further 7 days of continuous ECG monitoring via VitalConnect patch as an outpatient at 3 months post hospital discharge.
Adducts of Diisocyanates and Methacryloyl Alkyl Ethers, Alkoxy-benzenes, or Alkoxycycloalkanes, Compositions Containing Such Compounds, and Method of Use Thereof. ABSTRACT OF DISCLOSURE Polymerizable adducts of diisocyanates and methacryloyl alkyl ethers, alkoxybenzenes, or alkoxycycloalkanes are disclosed. The compounds of the present invention are formed into compositions which are useful as bone cement, fillings for cavities, and orthodontic adhesives. The compositions have improved mechanical properties, low water absorption, and excellent color and discoloration stability, coupled with a high filler content. This Application claims the priority of European Patent Application No. 80104311.8, filed on July 23,1980.
There are many barriers that prevent people with lower limb amputations (LLA) from receiving effective nonpharmacological treatment for their phantom limb pain (PLP), such as long outpatient wait times and the sparse number of amputation rehabilitation specialists. Early administration of effective PLP treatments, such as graded motor imagery (GMI), may improve both treatment access and efficacy if it is administered through virtual reality (VR). However, no VR GMI treatments have been developed or tested in the acute postoperative period following LLA to prevent PLP. The current study will recruit 30 patients being treated for LLA at the Health Sciences Centre (HSC) in Winnipeg, Manitoba to assess the feasibility and pilot outcomes of a novel VR GMI program administered in the postoperative acute care setting, with the goal of preventing and or reducing PLP. First, the researchers predict the mean acceptability, tolerability, and length of engagement in the VR program will be high across administration contexts and each of the VR stages. Second, the researchers hypothesize the recruitment strategies employed will capture and retain a large, representative sample of individuals undergoing LLA at the HSC. Lastly, the researchers predict length of VR program engagement will demonstrate a preliminary effect on PLP incidence, intensity, and interference at one-month follow-up. Baseline characteristics such as anxiety, depression, and amputation etiology will also be explored as extraneous variables. This research will be the first to provide evidence for the feasibility of VR PLP treatment administered immediately following LLA. The results will inform future development of the VR program and optimize the study procedures for an upcoming randomized clinical trial.
The program will consist of 12 sessions of peer mentoring that will include one standard educational session by telephone or video for approximately 60 minutes every 2 weeks. Additional interaction will be discouraged, but mentees and mentors will be asked to report any additional social interaction should it occur. The bi-weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. 60-minute calls are necessary for the delivery of educational content and mentors and mentees to be able to discuss their own experiences and potential solutions.
PURPOSE:To obtain the titled stable sheet or tape having high bioavailability, easily, by forming a hard component layer composed mainly of a high-molecular weight polymer on a substrate, laminating a tackifying layer containing the principal drug component on the hard component layer, and integrating both layers to form a pressure-sensitive adhesive layer. CONSTITUTION:A hard component layer composed mainly of a high-molecular weight polymer and containing <=1/3 of the drug component is applied to the surface of a substrate. The hard component layer is laminated with a tackifying layer composed mainly of a tackifier and containing >=2/3 of the drug component. Both layers are integrated and imparted with the function of the pressure- sensitive adhesive layer to obtain the fitted sheet or tape. The tackifier is a low-molecular weight polymer composed of the same monomer as that of the high-molecular weight polymer, or a low-molecular weight polymer having similar polarity. It can be mixed with the high-molecular weight polymer at an arbitrary ratio, and exhibits the function of stable tackifier. The absorbability of the drug component is high, and the sheet has no toxicity to the skin.
Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile. Study participants also receive 6 sessions of TMD disease management.
Comparative group for the Pakistani WHZ \<-2 children who undergo UGI endoscopy and biopsy. Environmental Enteropathy and celiac disease have some shared features therefore we plan to enroll children under the age of 6 years with newly diagnosed celiac disease per endoscopy at CCHMC to assess the extent to which gene signatures and associated biologic pathways for children with celiac disease or environmental enteropathy overlap or differ.
All patients enrolled in the trial will undergo 3 PET/CT studies using 11C-acetate at the injected radiotracer. The patients will be imaged prior to their radiation therapy and at 1 and 3 months following the completion of their radiation therapy. They will also undergo an MRI scan of the liver at each of those time points.
Participants will use an app to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores daily for 2 weeks post-op \& weekly for another 4 weeks. Surgeons will use a wireless interface to access that data and monitor the patient's condition. Participants will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, followup-related financial costs, and telemedicine satisfaction at 2 \& 6 weeks post-op. They will attend prescribed follow-up appointments with their surgeon with the option to skip 1 or more follow-up appointments dependent on their recovery trajectory \& surgeon.
PROBLEM TO BE SOLVED: To provide a sheet member for a skin which has a new concept different from the conventional sheet members for a skin.SOLUTION: A sheet member for a skin comprises a film base material and an adhesive layer constituted of a reversible adhesive agent as major constituent elements. The sheet member for a skin is used by attaching a surface of the adhesive layer to the skin in which a skin lotion, etc. containing a cosmetic component is deposited to the surface of the adhesive layer, and can be reused after the use. The sheet member for a skin can be repeatedly used, after being used attaching to the skin and being cleaned after the use, by redeposition of the skin lotion, etc. containing the cosmetic component to the surface of the adhesive layer and attachment to the skin. When the sheet member for a skin is used, the cosmetic component can be selected according to the user's taste, or depending on the season or the status of the skin. The sheet member for a skin is used for exerting cosmetic effect of a cosmetic pack and the like.SELECTED DRAWING: Figure 3
Participants received self-administered subcutaneous injections of evolocumab 140 mg on Day 1 and every 14 days thereafter until Day 336. Then, participants received subcutaneous injections of inclisiran 300 mg on Day 360 and every 180 days thereafter for up to 4 years.
BACKGROUND: Venoarterial extracorporeal membrane oxygenation (ECMO) provides full hemodynamic support for patients with cardiogenic shock, but optimal timing of ECMO initiation remains uncertain. We sought to determine whether earlier initiation of ECMO is associated with improved survival in cardiogenic shock.
METHODS AND RESULTS: We analyzed adult patients with cardiogenic shock who received venoarterial ECMO from the international Extracorporeal Life Support Organization (ELSO) registry from 2009 to 2019, excluding those cannulated following an operation. Multivariable logistic regression evaluated the association between time from admission to ECMO initiation and in-hospital death. Among 8619 patients (median, 56.7 [range, 44.8-65.6] years; 33.5% women), the median duration from admission to ECMO initiation was 14 (5-32) hours. Patients who had ECMO initiated within 24 hours (n=5882 [68.2%]) differed from those who had ECMO initiated after 24 hours, with younger age, more preceding cardiac arrest, and worse acidosis. After multivariable adjustment, patients with ECMO initiated >24 hours after admission had higher risk of in-hospital death (adjusted odds ratio, 1.20 [95% CI, 1.06-1.36]; P=0.004). Each 12-hour increase in the time from admission to ECMO initiation was incrementally associated with higher adjusted in-hospital mortality rate (adjusted odds ratio, 1.06 [95% CI, 1.03-1.10]; P<0.001). The association between longer time to ECMO and worse outcomes appeared stronger in patients with lower shock severity.
CONCLUSIONS: Longer delays from admission to ECMO initiation were associated with higher a mortality rate in a large-scale, international registry. Our analysis supports optimization of door-to-support time and the avoidance of inappropriately delayed ECMO initiation.
PROBLEM TO BE SOLVED: To obtain the subject produced solution easy in production, capable of easily eliminating superoxide anion radicals and useful for medicines by including free hydrogen ions obtained by neutralizing hydroxide ions produced by the electrolysis of an electrolyte solution with a specific acid. SOLUTION: This produced solution containing free hydrogen ions contains hydrogen ions (H<+> ) which are obtained by electrolyzing an electrolyte solution (using e.g. sodium chloride as an electrolytic auxiliary) by the use of inactive electrodes such as platinum electrodes through e.g. a diaphragm (concretely an anion or cation exchange membrane) or the like to produce free hydroxide ions (OH<-> ) on the cathode side, and subsequently neutralizing the produced electrolyte solution with ascorbic acid to produce the free hydrogen ions (H<+> ) (e.g. a compound of formula I is neutralized with OH<-> ions to produce a compound of formula II and the H<+> ).  The produced solution is obtained by using e.g. an electrolyte solution having an electrolyte concentration of >=10<-4> mole/L and a free anion and cation concentration of 10<-4> to 10<-2> mole/L as the component A and electrolyzing the solution with an applied direct electric current of 0.25-25 A/L.
In 2019, tuberculosis (TB) remained the leading cause of death due to a single infectious pathogen. An estimated 10 million people had TB worldwide, with 1.2 million TB fatalities among Human immune deficiency virus (HIV)-negative people and 208, 000 deaths among HIV-positive people. Literature indicated that treatment adherence for coinfections diseases is difficult due to the complexity, low tolerability, and extended duration of current treatment regimens, especially for both drug-susceptible and drug-resistant TB. There is a need for continuing the quest for low-cost, reliable, and acceptable measures of adherence for the treatment of TB and HIV co-infection. A qualitative approach and pharmacist-led intervention are needed to improve the adherence level of medication for TB patients. The study is aimed to investigate the degree of adherence and evaluate its impacts on clinical outcomes in TB and HIV co-infected patients. To determine the uptake and usage of the intervention, the study will include nested qualitative and economic evaluation sub-studies as well as a process evaluation. A longitudinal study design will adopt to carry out the present study, involving TB and HIV co-infected patients in either the pharmacist-led intervention (adherence and medication reminder, follow-up reminders, and counselling) or control arm. To determine the uptake and usage of the intervention, the study will include theoretical and conceptual models and theories. The study will conclude with targeted efforts of Pharmacist led intervention to improve and sustain excellent adherence in the real-world clinical setting which is critical for maximizing the effectiveness of each medication and treatment. These innovative technologies can thereby be harnessed to improve adherence to TB and HIV regimens in Malaysia and worldwide.
BACKGROUND: Lumbar disc surgery is among the more common spinal procedures. In this paper, we report the current treatment recommendations for patients with symptomatic disc herniation.
METHODS: This review is based on pertinent publications retrieved by a selective literature search in PubMed using the terms [timing] AND [lumbar disc herniation], supplemented by other relevant articles and guidelines.
RESULTS: Symptoms resolve in 60% to 80% of patients with herniated discs in 6-12 weeks, and in 80% to 90% over the long term (≥ 1 year). According to the guidelines, 6-12 weeks of conservative treatment are recommended in the absence of significant neu - rologic deficits. Early surgery is indicated in case of worsening pain or new onset of neurologic deficits. Lumbar disc herniation associated bladder or bowel dysfunction (cauda equina syndrome) is considered an absolute surgical emergency that requires immediate decompression (within 24 to 48 hours). Patients with severe motor deficits (MRC ≤ 3/5) benefit from early intervention and should be offered surgery within three days, if possible, for the best chance of recovery. The degree of weakness and the duration of symptoms have been identified as risk factors for incomplete recovery. Early surgery can be considered in patients with mild paresis (MRC 4/5) in case of functional impairment (e.g., quadriceps paresis).
CONCLUSION: Longer symptom duration and lower motor scores are associated with worse outcome and a lower chance of neurologic recovery. The recovery rate for motor deficits ranges from 33% to 75%, depending on the timing and modality of treatment as well as the motor score.
Lethal Toxin Neutralizing Factor has been isolated in purity from opossum serum by high pressure liquid chromatography (HPLC) fractionation. The amino acid sequence from the N-terminal for the first fifteen amino acids of LTNF-n is: Leu Lys Ala Met Asp Pro Thr Pro Pro Leu Trp Ile Lys Thr Glu. Antibodies to LTNF-n and synthetic peptides consisting of fifteen, ten and five amino acids from the N-terminal of the above sequence, designated as LTNF-15, LTNF-10 and LTNF-5 were produced by immunizing Balb/C mice to produce Anti-LTNF-n, Anti-LTNF-15, Anti-LTNF-10 and Anti-LTNF-5. The anti LTNF-n, anti-LTNF-15, anti-LTNF-10 and anti-LTNF-5 react immunologically with all types of toxins derived from animal, plant and bacteria and can be assayed by immunological in vitro test such as ELISA tests. Anti-LTNFs react roughly proportional to lethal dose of biological toxins under in vitro immunological ELISA test similar to the mouse bioassay test. This property of anti-LTNFs can be utilized to replace the use of animals for bioassay of toxins from animal, plant and bacteria. Anti-LTNFs can be polyclonal raised in animals or monoclonal made in hybridomas. Anti-LTNFs can be used in crude form for immunological in vitro testing. However, purified IgG from the anti LTNFs is most desirable for consistent results from the in vitro tests. In general, the in vitro use of Anti-LTNFs is a replacement for animal use as is currently required for the assay of biological toxins.
To provide a method for manufacturing a face mask sheet easily impregnated with skin lotion, providing a user with a favorable sense of use, and capable of favorably retaining cosmetic components, or for manufacturing a cosmetic puff filling for patting.SOLUTION: A cotton fiber group is made to pass through a carding machine and is spread to acquire a cotton fiber web. A cotton blending group formed by mixing the cotton fiber group and a thermally bondable fiber group is made to pass through the carding machine and is spread to acquire a cotton blending fiber web. A high-pressure water stream is applied to a laminate web formed by laminating the cotton fiber web and the cotton blending fiber web to acquire fiber fleece 1 and 1'. A powder group of powder composed of a water-soluble cosmetic component and powder composed of water-soluble thickening component is placed on the cotton blending fiber web side of the fiber fleece 1. The fiber fleece 1 and fiber fleece 1' are superposed, with the cotton blending fiber web side of the fiber fleece 1' brought into contact with the power group, to acquire a laminate fiber fleece 3. Heat and pressure are applied to the laminate fiber fleece 3 to bond the fiber fleece 1 and fiber fleece 1' so as to acquire a face mask sheet or a cosmetic puff filling for patting.SELECTED DRAWING: Figure 1
The investigators are implementing an enhanced recovery after surgery (ERAS) protocol for patients undergoing cesarean delivery. The purpose of the ERAS protocol is to optimize care provided to patients (patient education, nutrition, pain management, early ambulation, etc.). The anticipated date of protocol initiation is May 2018. Once this protocol has been in place for approximately 6 months to one year, the investigators would like to retrospectively review data on these patients and compare outcomes to a similarly-matched group of patients the year preceding protocol implementation. Specific outcomes the investigators will assess are: hospital length of stay, post-operative pain scores, opioid consumption, patient satisfaction \[through IRB-approved survey (protocol X300001121)\], surgical site infection rates, readmission rates, and unscheduled clinic and maternal evaluation unit (MEU) visits before the first scheduled postpartum visit. The investigators also plan to track compliance monthly with the adherence to the protocol. Since the investigators want to track compliance (both as a quality improvement project as well as research), the investigators are requesting (Institutional Review Board) IRB approval now.
The present invention relates to a mask pack. A first liquid agent is accommodated in a first accommodation part (11) formed in a pouch (1) to be separated. A second liquid agent is separately accommodated in a second accommodation part (12). When in use, the first agent and the second agent are mixed in the pouch and applied to the skin. The first liquid agent and the second liquid agent are separately accommodated in one pouch, and when used, the first agent and the second agent can be easily and uniformly mixed to be used as a mask pack. Therefore, the existing problems that it is difficult for a user to make a uniform mixture due to a powder form and there is severe irritation in part when applied to the skin due to non-uniform mixing are solved. As the present invention does not require a separate container, water, and spatula, the convenience of use is improved. Further, a customized mask pack can be manufactured depending on the user′s skin condition by adding various functional medicinal extracts.